Bone marrow-derived mesenchymal stromal cells improve vascular regeneration and reduce leukocyte-endothelium activation in critical ischemic murine skin in a dose-dependent manner

Cytotherapy

Volumn 16, Issue 10, 2014, Pages 1345-1360

  Schweizer, Riccardo ^a,b   Kamat, Pranitha ^a,b   Schweizer, Dennis ^b   Dennler, Cyrill ^b   Zhang, Shengye ^b   Schnider, Jonas T ^b   Salemi, Souzan ^c   Giovanoli, Pietro ^a   Eberli, Daniel ^c   Enzmann, Volker ^b   Erni, Dominique ^b   Plock, Jan A ^a,b,c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Angiogenesis; Arteriogenesis; Conditioned medium; Immunomodulation; Mesenchymal stromal cells; Paracrine function; Vascular regeneration

Indexed keywords

ANGIOPOIETIN 2; CHEMOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; KERATINOCYTE CHEMOATTRACTANT; MITOGEN ACTIVATED PROTEIN KINASE P38; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTERIOLE; ARTICLE; BLOOD VESSEL DIAMETER; BONE MARROW DERIVED MESENCHYMAL STROMAL CELL; CAPILLARY DENSITY; CELL THERAPY; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM; FEMALE; FLUORESCENCE ANALYSIS; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; ISCHEMIA; LEUKOCYTE ACTIVATION; LEUKOCYTE ADHERENCE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SKIN DISEASE; SKIN FLAP; VASODILATATION; VENULE; WESTERN BLOTTING; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CAPILLARY; CELL COMMUNICATION; CELL CULTURE; IMMUNOLOGY; LEUKOCYTE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REGENERATION; SKIN; VASCULARIZATION;

MURINAE;

ANIMALS; BONE MARROW CELLS; CAPILLARIES; CELL COMMUNICATION; CELLS, CULTURED; ENDOTHELIUM; FEMALE; ISCHEMIA; LEUKOCYTES; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; REGENERATION; SKIN;

EID: 84908512584     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.05.008     Document Type: Article

References (81)

1. Tolar J., Le Blanc K., Keating A., Blazar B.R. Concise review: hitting the right spot with mesenchymal stromal cells. Stem Cells 2010, 28:1446-1455.
2. Caplan A.I. Why are MSCs therapeutic? New data: new insight. JPathol 2009, 217:318-324.
3. Caplan A.I., Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011, 9:11-15.
4. Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
5. Iso Y., Spees J.L., Serrano C., Bakondi B., Pochampally R., Song Y., et al. Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftment. Biochem Biophys Res Commun 2007, 354:700-706.
6. Kinnaird T., Stabile E., Burnett M.S., Lee C.W., Barr S., Fuchs S., et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res 2004, 94:678-685.
7. Tse H., Siu C., Zhu S., Songyan L., Zhang Q., Lai W., et al. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischaemic myocardium. Eur J Heart Failure 2007, 9:747-753.
8. Potente M., Gerhardt H., Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
9. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
10. Wang T., Sun S., Wan Z., Weil M.H., Tang W. Effects of bone marrow mesenchymal stem cells in a rat model of myocardial infarction. Resuscitation 2012, 83:1391-1396.
11. Asahara T., Takahashi T., Masuda H., Kalka C., Chen D., Iwaguro H., et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999, 18:3964-3972.
12. Kinnaird T., Stabile E., Burnett M.S., Shou M., Lee C.W., Barr S., et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation 2004, 109:1543-1549.
13. Schlosser S., Dennler C., Eberli D., Schweizer R. Paracrine effects of mesenchymal stem cells enhance vascular regeneration in ischemic murine skin. Microvasc Res 2012, 83:267-275.
14. Boomsma R.A., Geenen D.L. Mesenchymal stem cells secrete multiple cytokines that promote angiogenesis and have contrasting effects on chemotaxis and apoptosis. PloS One 2012, 7:e35685.
15. Sadat S., Gehmert S., Song Y.H., Yen Y., Bai X., Gaiser S., et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-I and VEGF. Biochem Biophys Res Commun 2007, 363:674-679.
16. Nakagami H., Maeda K., Morishita R., Iguchi S., Nishikawa T., Takami Y., et al. Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005, 25:2542-2547.
17. Gale N.W., Yancopoulos G.D. Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. Genes Dev 1999, 13:1055-1066.
18. Tressel S.L., Kim H., Ni C., Chang K., Velasquez-Castano J.C., Taylor W.R., et al. Angiopoietin-2 stimulates blood flow recovery after femoral artery occlusion by inducing inflammation and arteriogenesis. Arterioscl Thromb Vasc Biol 2008, 28:1989-1995.
19. Lekas M., Lekas P., Mei S.H., Deng Y., Dumont D.J., Stewart D.J. Tie2-dependent neovascularization of the ischemic hindlimb is mediated by angiopoietin-2. PloS One 2012, 7:e43568.
20. Singer N.G., Caplan A.I. Mesenchymal stem cells: mechanisms of inflammation. Annu Rev Pathol 2011, 6:1-24.
21. Meirelles L.S., Fontes A.M., Covas D.T., Caplan A.I. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20:419-427.
22. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., et al. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106:1755-1761.
23. Xu J., Wang D., Liu D., Fan Z., Zhang H., Liu O., et al. Allogeneic mesenchymal stem cell treatment alleviates experimental and clinical Sjogren syndrome. Blood 2012, 120:3142-3151.
24. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81:1390-1397.
25. Kuo Y.R., Chen C.C., Goto S., Lee I.T., Huang C.W., Tsai C.C., et al. Modulation of immune response and T-cell regulation by donor adipose-derived stem cells in a rodent hind-limb allotransplant model. Plast Reconstr Surg 2011, 128:661e-672e.
26. Boxall S.A., Jones E. Markers for characterization of bone marrow multipotential stromal cells. Stem Cells Int 2012, 2012:975871.
27. Akker F., Deddens J.C., Doevendans P.A., Sluijter J.P. Cardiac stem cell therapy to modulate inflammation upon myocardial infarction. Biochim Biophys Acta 2012, 1830:2449-2458.
28. Atkins S., Loescher A.R., Boissonade F.M., Smith K.G., Occleston N., O'Kane S., et al. Interleukin-10 reduces scarring and enhances regeneration at a site of sciatic nerve repair. JPeripher Nerv Syst 2007, 12:269-276.
29. Lee R.H., Pulin A.A., Seo M.J., Kota D.J., Ylostalo J., Larson B.L., et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009, 5:54-63.
30. Tateishi-Yuyama E., Matsubara H., Murohara T., Ikeda U., Shintani S., Masaki H., et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002, 360:427-435.
31. Turan R.G., Bozdag-Turan I., Ortak J., Akin I., Kische S., Schneider H., et al. Improved mobilization of the CD34(+) and CD133(+) bone marrow-derived circulating progenitor cells by freshly isolated intracoronary bone marrow cell transplantation in patients with ischemic heart disease. Stem Cells Dev 2011, 20:1491-1501.
32. Wollert K.C., Meyer G.P., Lotz J., Ringes-Lichtenberg S., Lippolt P., Breidenbach C., et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004, 364:141-148.
33. Atkins S., Smith K.G., Loescher A.R., Boissonade F.M., O'Kane S., Ferguson M.W., et al. Scarring impedes regeneration at sites of peripheral nerve repair. Neuroreport 2006, 17:1245-1249.
34. Reed D.M., Foldes G., Harding S.E., Mitchell J.A. Stem cell derived endothelial cells for cardiovascular disease; a therapeutic perspective. Br J Clin Pharmacol 2013, 75:897-906.
35. Karp J.M., Teo G.S. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009, 4:206-216.
36. Assis A.C., Carvalho J.L., Jacoby B.A., Ferreira R.L., Castanheira P., Diniz S.O., et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant 2010, 19:219-230.
37. Schrepfer S., Deuse T., Reichenspurner H., Fischbein M.P., Robbins R.C., Pelletier M.P. Stem cell transplantation: the lung barrier. Transplant Proc 2007, 39:573-576.
38. Eggenhofer E., Benseler V., Kroemer A., Popp F.C., Geissler E.K., Schlitt H.J., et al. Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol 2012, 3:297.
39. Santo S., Yang Z., Ballmoos M.W., Voelzmann J., Diehm N., Baumgartner I., et al. Novel cell-free strategy for therapeutic angiogenesis: in vitro generated conditioned medium can replace progenitor cell transplantation. PloS One 2009, 4:e5643.
40. Hung S.C., Pochampally R.R., Chen S.C., Hsu S.C., Prockop D.J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25:2363-2370.
41. Osugi M., Katagiri W., Yoshimi R., Inukai T., Hibi H., Ueda M. Conditioned media from mesenchymal stem cells enhanced bone regeneration in rat calvarial bone defects. Tissue Eng Part A 2012, 18:1479-1489.
42. Phinney D.G., Kopen G., Isaacson R.L., Prockop D.J. Plastic adherent stromal cells from the bone marrow of commonly used strains of inbred mice: variations in yield, growth, and differentiation. JCell Biochem 1999, 72:570-585.
43. Schweizer R., Merz K., Schlosser S., Spanholtz T., Contaldo C., Stein J.V., et al. Morphology and hemodynamics during vascular regeneration in critically ischemic murine skin studied by intravital microscopy techniques. Eur Surg Res 2011, 47:222-230.
44. Schlosser S., Spanholtz T., Merz K., Dennler C., Banic A., Erni D., et al. The choice of anesthesia influences oxidative energy metabolism and tissue survival in critically ischemic murine skin. JSurg Res 2010, 162:308-313.
45. Erni D., Sakai H., Banic A., Tschopp H.M., Intaglietta M. Quantitative assessment of microhemodynamics in ischemic skin flap tissue by intravital microscopy. Ann Plast Surg 1999, 43:405-414. discussion 14-5.
46. Plock J.A., Tromp A.E., Contaldo C., Spanholtz T., Sinovcic D., Sakai H., et al. Hemoglobin vesicles reduce hypoxia-related inflammation in critically ischemic hamster flap tissue. Crit Care Med 2007, 35:899-905.
47. Klyscz T., Jünger M., Jung F., Zeintl H. [Cap-Image-a new kind of computer-assisted video image analysis system for dynamic capillary microscopy]. Biomed Tech (Berl) 1997, 42:168-175. [in German].
48. Plock J.A., Contaldo C., Sakai H., Tsuchida E., Leunig M., Banic A., et al. Is hemoglobin in hemoglobin vesicles infused for isovolemic hemodilution necessary to improve oxygenation in critically ischemic hamster skin?. Am J Physiol Heart Circ Physiol 2005, 289:H2624-H2631.
49. Han Y., Liu L., Yan D., Wang G. Correlation between expression of P38 MAPK-signaling and uPA in breast cancer. Chin J Clin Oncol 2008, 5:161-164.
50. Shim W.S., Tan G., Gu Y., Qian L., Li S., Chung Y.Y., et al. Dose-dependent systolic contribution of differentiated stem cells in post-infarct ventricular function. JHeart Lung Transpl 2010, 29:1415-1426.
51. Nan H., Gao J.H., Lu F., Fu B.C. [Transplantation of adipose tissue-derived stem cells promotes soft tissue wound repair in rats]. Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:2633-2636. [inChinese].
52. Wu J., Sun Z., Sun H.S., Weisel R.D., Keating A., Li Z.H., et al. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant 2008, 16:993-1005.
53. Schenk S., Mal N., Finan A., Zhang M., Kiedrowski M., Popovic Z., et al. Monocyte chemotactic protein-3 is a myocardial mesenchymal stem cell homing factor. Stem Cells 2007, 25:245-251.
54. Omori Y., Honmou O., Harada K., Suzuki J., Houkin K., Kocsis J.D. Optimization of a therapeutic protocol for intravenous injection of human mesenchymal stem cells after cerebral ischemia in adult rats. Brain Res 2008, 1236:30-38.
55. Heil M., Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res 2004, 95:449-458.
56. Merz K., Schlosser S., Giovanoli P., Schweizer R. Distinct microhemodynamic efficacy of arteriogenesis and angiogenesis in critically ischemic skin flaps. Microvascular 2012, 83:249-256.
57. Miranville A., Heeschen C., Sengenes C., Curat C.A., Busse R., Bouloumie A. Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004, 110:349-355.
58. Reichenberger M.A., Heimer S., Schaefer A., Lass U., Gebhard M.M., Germann G., et al. Adipose derived stem cells protect skin flaps against ischemia-reperfusion injury. Stem Cell Rev 2012, 8:854-862.
59. Cunha F.F., Martins L., Martin P.K., Stilhano R.S., Han S.W. Acomparison of the reparative and angiogenic properties of mesenchymal stem cells derived from the bone marrow of BALB/c and C57/BL6 mice in a model of limb ischemia. Stem Cell Res Ther 2013, 4:86.
60. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med 2000, 6:389-395.
61. Felcht M., Luck R., Schering A., Seidel P., Srivastava K., Hu J., et al. Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. JClin Invest 2012, 122:1991-2005.
62. Loukovaara S., Robciuc A., Holopainen J.M., Lehti K., Pessi T., Liinamaa J., et al. Ang-2 upregulation correlates with increased levels of MMP-9, VEGF, EPO and TGFβ1 in diabetic eyes undergoing vitrectomy. Acta Ophthalmol 2013, 91:531-539.
63. Thomas M., Augustin H.G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 2009, 12:125-137.
64. Korff T., Kimmina S., Martiny-Baron G., Augustin H.G. Blood vessel maturation in a 3-dimensional spheroidal coculture model: direct contact with smooth muscle cells regulates endothelial cell quiescence and abrogates VEGF responsiveness. FASEB J 2001, 15:447-457.
65. Eton D., Yu H. Enhanced cell therapy strategy to treat chronic limb-threatening ischemia. JVasc Surg 2010, 52:199-204.
66. Kawada H., Fujita J., Kinjo K., Matsuzaki Y., Tsuma M., Miyatake H., et al. Nonhematopoietic mesenchymal stem cells can be mobilized and differentiate into cardiomyocytes after myocardial infarction. Blood 2004, 104:3581-3587.
67. Ziegelhoeffer T., Fernandez B., Kostin S., Heil M., Voswinckel R., Helisch A., et al. Bone marrow-derived cells do not incorporate into the adult growing vasculature. Circ Res 2004, 94:230-238.
68. Wang C.H., Cherng W.J., Yang N.I., Kuo L.T., Hsu C.M., Yeh H.I., et al. Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol 2008, 28:54-60.
69. Asahara T., Kawamoto A., Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011, 29:1650-1655.
70. Frangogiannis N.G. The immune system and cardiac repair. Pharmacol Res 2008, 58:88-111.
71. Mulivor A.W., Lipowsky H.H. Inflammation- and ischemia-induced shedding of venular glycocalyx. Am J Physiol Heart Circ Physiol 2004, 286:H1672-H1680.
72. Pati S., Gerber M.H., Menge T.D., Wataha K.A., Zhao Y., Baumgartner J.A., et al. Bone marrow derived mesenchymal stem cells inhibit inflammation and preserve vascular endothelial integrity in the lungs after hemorrhagic shock. PloS One 2011, 6:e25171.
73. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
74. Ohnishi S., Yasuda T., Kitamura S., Nagaya N. Effect of hypoxia on gene expression of bone marrow-derived mesenchymal stem cells and mononuclear cells. Stem Cells 2007, 25:1166-1177.
75. Thomas J., Liu F., Link D.C. Mechanisms of mobilization of hematopoietic progenitors with granulocyte colony-stimulating factor. Curr Opin Hematol 2002, 9:183-189.
76. Son D.S., Roby K.F. Interleukin-1alpha-induced chemokines in mouse granulosa cells: impact on keratinocyte chemoattractant chemokine, a CXC subfamily. Mol Endocrinol 2006, 20:2999-3013.
77. Lira S.A., Zalamea P., Heinrich J.N., Fuentes M.E., Carrasco D., Lewin A.C., et al. Expression of the chemokine N51/KC in the thymus and epidermis of transgenic mice results in marked infiltration of a single class of inflammatory cells. JExp Med 1994, 180:2039-2048.
78. Frangogiannis N.G. Regulation of the inflammatory response in cardiac repair. Circ Res 2012, 110:159-173.
79. Mann D.L. The emerging role of innate immunity in the heart and vascular system: for whom the cell tolls. Circ Res 2011, 108:1133-1145.
80. Amado L.C., Saliaris A.P., Schuleri K.H., St John M., Xie J.S., Cattaneo S., et al. Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 2005, 102:11474-11479.
81. Menger M.D., Pelikan S., Steiner D., Messmer K. Microvascular ischemia-reperfusion injury in striated muscle: significance of "reflow paradox". Am J Physiol 1992, 263:H1901-H1906.